Tenaya Therapeutics Stock Investor Sentiment

TNYA Stock  USD 2.38  0.22  10.19%   
About 57% of Tenaya Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tenaya Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Tenaya Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Tenaya Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Tenaya Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tenaya Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at gurufocus.com         
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635
Gurufocus Stories at Macroaxis
3 days ago at investing.com         
Tenaya Therapeutics SVP sells 4,786 in stock
Investing News at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 2258 shares by Chihiro Saito of Tenaya Therapeutics at 2.12 subject to Rule 16b-3
Macroaxis News
six days ago at gurufocus.com         
RA Capital Managements Strategic Acquisition in Tenaya Therapeutics
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Tenaya Therapeutics Given New 18.00 Price Target at Chardan Capital
news
over a week ago at simplywall.st         
Tenaya Therapeutics, Inc.s large institutional owners must be happy as stock continues to impress, u...
Simply Wall St News at Macroaxis
over two weeks ago at seekingalpha.com         
Tenaya Therapeutics GAAP EPS of -0.30
seekingalpha News
over two weeks ago at finance.yahoo.com         
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Yahoo News
over two weeks ago at finance.yahoo.com         
Heres Why Were Watching Tenaya Therapeutics Cash Burn Situation
Yahoo News
over three weeks ago at news.google.com         
Tenaya Therapeutics, Inc. Given Consensus Rating of Buy by Analysts - MarketBeat
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Tenaya Therapeutics, Inc. Given Consensus Rating of Buy by Analysts
news
over a month ago at news.google.com         
TNYA Stock Earnings Tenaya Therapeutics Beats EPS for Q1 2024 - MSN
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 subject to Ru...
Macroaxis News
over two months ago at finance.yahoo.com         
Owning 43 percent shares,institutional owners seem interested in Tenaya Therapeutics, Inc. ,
Yahoo News
Far too much social signal, news, headlines, and media speculation about Tenaya Therapeutics that are available to investors today. That information is available publicly through Tenaya media outlets and privately through word of mouth or via Tenaya internal channels. However, regardless of the origin, that massive amount of Tenaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenaya Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenaya Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenaya Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenaya Therapeutics alpha.

Tenaya Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Tenaya Therapeutics Announces Board Restructuring and New Equity Plan - TipRanks
09/16/2024
2
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 subject to Rule 16b-3
09/26/2024
3
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to Rule 16b-3
10/18/2024
4
Tenaya Therapeutics GAAP EPS of -0.30
11/07/2024
5
RA Capital Managements Strategic Acquisition in Tenaya Therapeutics
11/15/2024
6
Disposition of 2258 shares by Chihiro Saito of Tenaya Therapeutics at 2.12 subject to Rule 16b-3
11/18/2024
7
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635
11/19/2024

Complementary Tools for Tenaya Stock analysis

When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities